Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Daiichi Sankyo
Johnson and Johnson
Healthtrust
Dow
AstraZeneca
Express Scripts
Chinese Patent Office
Baxter

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,541,466

« Back to Dashboard

Which drugs does patent 8,541,466 protect, and when does it expire?

Patent 8,541,466 protects LATISSE and is included in one NDA.

This patent has sixteen patent family members in nine countries.
Summary for Patent: 8,541,466
Title:Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
Inventor(s): DeLong; Mitchell Anthony (Raleigh, NC), McIver; John McMillan (Cincinnati, OH), Youngquist; Robert Scott (Mason, OH)
Assignee: Duke University (Durham, NC)
Application Number:12/535,513
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 8,541,466

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF INCREASING HAIR GROWTH ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,541,466

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,579,270 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins ➤ Sign Up
7,388,029 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins ➤ Sign Up
8,906,962 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Cantor Fitzgerald
Fish and Richardson
Harvard Business School
Chubb
UBS
McKesson
Healthtrust
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.